WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
P.O.Box 4404 Nydalen
0403 Oslo
Norway

Visiting/delivery address:
Marcus Thranes gate 6
0473 Oslo
Norway

Tel:  +47 21 07 81 60
Fax: +47 21 07 81 46
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

This group comprises preparations used in the treatment of malignant neoplastic diseases, and immunomodulating agents.

Corticosteroids for systemic use, see H02.


L02 ENDOCRINE THERAPY

Estrogens and progestogens used specifically in the treatment of neoplastic diseases are classified in this group. This means that some strengths may be classified in this group, while remaining strengths are classified in G03 - Sex hormones and modulators of the genital system.

The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).


L02B HORMONE ANTAGONISTS AND RELATED AGENTS

L02BA Anti-estrogens
L02BB Anti-androgens
L02BG Aromatase inhibitors
L02BX Other hormone antagonists and related agents

Last updated: 2013-12-19